Patents by Inventor Patrick Baeuerle

Patrick Baeuerle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12128102
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: July 21, 2023
    Date of Patent: October 29, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Patrick Baeuerle, Robert B. DuBridge, Holger Wesche, Luke Evnin, Jeanmarie Guenot, Anand Panchal, Maia Vinogradova
  • Publication number: 20240301026
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs). T-cells engineered to express one or more TFPs. and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: March 8, 2024
    Publication date: September 12, 2024
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Patent number: 12084518
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: September 10, 2024
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
  • Patent number: 11981716
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: May 14, 2024
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 11965012
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: April 23, 2024
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Publication number: 20240101630
    Abstract: Disclosed herein are immunomodulatory fusion proteins comprising an IL-2; an IL-12, a collagen-binding domain, and a linear polypeptide spacer, methods of making and using the same. The immunomodulatory fusion proteins disclosed herein are useful for the treatment of cancer.
    Type: Application
    Filed: December 17, 2021
    Publication date: March 28, 2024
    Inventors: Naveen Mehta, Jennifer Michaelson, Patrick Baeuerle, Li Bochong, Dane K. Wittrup
  • Patent number: 11851491
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 26, 2023
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Robert Hofmeister
  • Publication number: 20230374093
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: October 9, 2022
    Publication date: November 23, 2023
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Patent number: 11753475
    Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 12, 2023
    Assignee: AMGEN INC.
    Inventors: Luis G. Borges, Patrick A. Baeuerle, Wei Yan, Mark L. Michaels
  • Publication number: 20230235010
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 27, 2023
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Publication number: 20230212318
    Abstract: Described herein are protease-activatable proteins (PABPs), which, when activated, can mediate cytolysis of target cells by effector cells. Also provided are nucleic acids encoding such PABPs and methods of making and using PABPs.
    Type: Application
    Filed: April 22, 2022
    Publication date: July 6, 2023
    Inventors: Wei Yan, Martin J. Pentony, Mark L. Michaels, Patrick Baeuerle
  • Publication number: 20230212297
    Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 6, 2023
    Inventors: Luis G. Borges, Patrick Baeuerle, Wei Yan, Mark L. Michaels
  • Publication number: 20230037815
    Abstract: Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 9, 2023
    Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta, Jonathan Belk, Nathan Sharkey, Bianka Prinz, Bradley M. Lunde, Nga Rewa Houston
  • Publication number: 20230032087
    Abstract: The invention relates to anti-serum albumin antibodies and multi-specific binding proteins comprising the same. The invention also relates to pharmaceutical compositions comprising the antibodies or multi-specific binding proteins, expression vectors and host cells for making the antibodies or multi-specific binding proteins, and methods of use of the antibodies or multi-specific binding proteins in treatment of diseases or disorders.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 2, 2023
    Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta, Bianka Prinz, Bradley M. Lunde, Nga Rewa Houston
  • Patent number: 11535658
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: December 27, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 11535668
    Abstract: Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 27, 2022
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Holger Wesche
  • Publication number: 20220324930
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 13, 2022
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Patent number: 11453710
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: September 27, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20220298478
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 22, 2022
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Patent number: 11377638
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: July 5, 2022
    Assignee: TCR2 Therapeutics Inc.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister